Efficacy, safety and dosing of intravenous alteplase administered beyond 4.5 hours for ischemic stroke: systematic review and meta-analysis.

Key Points

• This research aims to evaluate the efficacy and safety of administering intravenous alteplase beyond 4.5 hours for ischemic stroke patients.
• Conducted systematic review and meta-analysis
• Included studies assessing alteplase timing and outcomes
• Analyzed functional outcomes, risks of hemorrhage, and mortality
• Improved functional outcomes noted in selected patients receiving alteplase beyond 4.5 hours
• Increased risk of symptomatic intracranial hemorrhage
• No significant effect on mortality observed

Abstract